Damora Therapeutics (DMRA) stock: insider trades, news & valuation
Health Care · Net buyingShare price and insider trades
Damora Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $253K and 3 sold $31K of DMRA stock on the open market.
Get emailed when insiders cluster-buy stocks like DMRA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
DMRA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $253K | 1 | $7K | 1 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $23K | 3 |
Valuation, profit and volume
Pick score 46/100Summary
Over the past 12 months, 1 Damora Therapeutics, Inc. insider reported open-market purchases totaling $253K, while 3 insiders reported sales totaling $31K. 0 of 4 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
DMRA stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 28SEC | Jennifer JarrettCEO, President | Buy | 12,500512,500 held (+2%) | $20.23 | $253K | +4.2% | — |
| Jul 7SEC | Garrett WinslowGeneral Counsel | Sell | 2452,289 held (−10%) | $29.98 | $7K | -29.7% | — |
| Jan 6SEC | Hans T. SchambyeCEO | Sell | 7004,682 held (−13%) | $21.38 | $15K | -1.4% | — |
| Jan 6SEC | Garrett WinslowGeneral Counsel | Sell | 2551,854 held (−12%) | $21.38 | $5K | -1.4% | — |
| Jan 6SEC | Lori FirmaniCFO | Sell | 135931 held (−13%) | $21.41 | $3K | -1.5% | — |
Insiders at Damora Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Jennifer JarrettCEO, President | $253K | — | Sep 28, 2026 | — |
| Hans T. SchambyeCEO | — | $15K | Jan 6, 2026 | — |
| Garrett WinslowGeneral Counsel | — | $13K | Jul 7, 2026 | — |
| Lori FirmaniCFO | — | $3K | Jan 6, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
DMRA stock: common questions
Are Damora Therapeutics, Inc. insiders buying DMRA stock?
In the past 12 months, 1 insiders reported open-market purchases of DMRA worth $253K. The latest was CEO, President Jennifer Jarrett bought $253K of DMRA at $20.23 — first open-market purchase in our records.
Are Damora Therapeutics, Inc. insiders selling DMRA stock?
3 insiders reported sales worth $31K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is DMRA's 52-week range?
Over the past year DMRA has traded between $4.95 and $34.14. It last closed at $21.08 on Oct 9, 2026.